The Prognostic Lung Fibrosis Consortium (PROLIFIC) was established by Celgene Corporation (a wholly owned subsidiary of Bristol-Myers Squibb) and the Pulmonary Fibrosis Foundation (PFF) to create and validate an assay for use during development of drugs for pulmonary fibrosis. Myriad RBM is developing a new multiplex biomarker assay for 12 biomarkers selected by the consortium. Validated biomarkers will help identify effective treatments and decrease drug approval times.
A longer-term goal is to use the biomarkers to predict which patients benefit the most from a particular treatment, enabling physicians to tailor the right therapeutic treatments to the right patients. Members of the consortium include: Bristol-Myers Squibb, Chiesi USA, Galapagos NV, Galecto, Genentech, Gilead Sciences, Lung Therapeutics, Novartis Institutes for BioMedical Research, OptiKira, PFF, Pliant Therapeutics, Tvardi Therapeutics, and Three Lakes Foundation.
To learn more about PROLIFIC, go here: